AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Pancreatic Ductal Carcinoma.

A new mouse study by researchers at the University of California (UC), San Diego, School of Medicine reveals that an enzyme ...

Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for ...

Researchers assessed the association of KRAS mutations in metastatic PDAC with the clinical outcomes and responses to first-line chemotherapy regimens.

Pancreatic cancer kills 50,000 people each year, according to the National Cancer Institute, and there are few effective ...

Pancreatic ductal adenocarcinoma remains a challenge to treat due to its complex biology and resistance mechanisms.

Background The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical ...

This discovery points to a new way to tackle pancreatic cancer. If scientists can find a way to block CD9 or stop the cancer ...

Read on to learn about new genomic biomarkers that could improve prognosis and treatment strategies for pancreatic ductal ...

Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies ...

Pancreatic cancer is one of the most lethal malignancies, with nearly 50,000 deaths annually in the United States, according ...